Structure-Based Virtual Screening of Protein Tyrosine Phosphatase Inhibitors: Significance, Challenges, and Solutions = Structure-Based Virtual Screening of Protein Tyrosine Phosphatase Inhibitors: Significance, Challenges, and Solutions

다국어 초록 (Multilingual Abstract)

Phosphorylation, a critical mechanism in biological systems, is estimated to be indispensable for about 30% of key biological activities, such as cell cycle progression, migration, and division. It is synergistically balanced by kinases and phosphatases, and any deviation from this balance leads to disease conditions. Pathway or biological activity-based abnormalities in phosphorylation and the type of involved phosphatase influence the outcome, and cause diverse diseases ranging from diabetes, rheumatoid arthritis, and numerous cancers. Protein tyrosine phosphatases (PTPs) are of prime importance in the process of dephosphorylation and catalyze several biological functions. Abnormal PTP activities are reported to result in several human diseases. Consequently, there is an increased demand for potential PTP inhibitory small molecules. Several strategies in structure-based drug designing techniques for potential inhibitory small molecules of PTPs have been explored along with traditional drug designing methods in order to overcome the hurdles in PTP inhibitor discovery. In this review, we discuss druggable PTPs and structure-based virtual screening efforts for successful PTP inhibitor design.

참고문헌 (Reference)

• 1 Zhang J, "miR-21, miR-17 and miR-19a induced by phosphatase of regenerating liver-3 promote the proliferation and metastasis of colon cancer" 107 : 352-359, 2012
• 2 Molina G, "Zebrafish chemical screening reveals an inhibitor of Dusp6 that expands cardiac cell lineages" 5 : 680-687, 2009
• 3 Irwin JJ, "ZINC - a free database of commercially available compounds for virtual screening" 45 : 177-182, 2005
• 4 Ye Z, "WHATIF: an open-source desktop application for extraction and management of the incidental findings from next-generation sequencing variant data" 68 : 165-169, 2016
• 5 Critton DA, "Visualizing active-site dynamics in single crystals of HePTP: opening of the WPD loop involves coordinated movement of the E loop" 405 : 619-629, 2011
• 6 Nogara PA, "Virtual screening of acetylcholinesterase inhibitors using the Lipinski’s rule of five and zinc databank" 2015 : 870389-, 2015
• 7 Stafford JA., "Use of high-throughput nanovolume crystallization in structure-based drug design" 226 : U460-U461, 2003
• 8 Sharma K, "Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thrbased signaling" 8 : 1583-1594, 2014
• 9 Song YS, "Trans-induced cis interaction in the tripartite NGL-1, netrin-G1 and LAR adhesion complex promotes development of excitatory synapses" 126 : 4926-4938, 2013
• 10 Hudaky P, "Toward direct determination of conformations of protein building units from multidimensional NMR experiments. VI. Chemical shift analysis of his to gain 3D structure and protonation state information" 26 : 1307-1317, 2005
• 11 Hinds PW, "Too much of a good thing: the Prl-3 in p53’s oyster" 30 : 260-261, 2008
• 12 Martell KJ, "The “VH1-like”dual-specificity protein tyrosine phosphatases" 8 : 2-11, 1998
• 13 Ananthaswamy N, "The signaling interface of the yeast multidrug transporter Pdr5 adopts a cis conformation, and there are functional overlap and equivalence of the deviant and canonical Q-loop residues" 49 : 4440-4449, 2010
• 14 Xiao P, "The second-sphere residue T263 is important for the function and catalytic activity of PTP1B via interaction with the WPD-loop" 57 : 84-95, 2014
• 15 Lauriol J, "The role of the protein tyrosine phosphatase SHP2 in cardiac development and disease" 37 : 73-81, 2015
• 16 Brandao TAS, "The molecular details of WPD-loop movement differ in the proteintyrosine phosphatases YopH and PTP1B" 525 : 53-59, 2012
• 17 Tamagawa H, "The expression of the phosphatase regenerating liver 3 gene is associated with outcome in patients with colorectal cancer" 59 : 2122-2126, 2012
• 18 Dong O, "The conserved Q-loop glutamine 1291 interacts with Ap(5)A" 47 : 240-, 2012
• 19 Claypool SM, "The complexity of cardiolipin in health and disease" 37 : 32-41, 2012
• 20 Vogt A, "The benzo[c] phenanthridine alkaloid, sanguinarine, is a selective, cell-active inhibitor of mitogenactivated protein kinase phosphatase-1" 280 : 19078-19086, 2005
• 21 Somvanshi P, "Targeting the peptide deformylase of Salmonella enterica for virtual screening and structure based drug designing" 25 : S366-, 2009
• 22 Krishnan N, "Targeting the disordered C terminus of PTP1B with an allosteric inhibitor" 10 : 558-566, 2014
• 23 Scott LM, "Targeting protein tyrosine phosphatases for anticancer drug discovery" 16 : 1843-1862, 2010
• 24 Chio CM, "Targeting a cryptic allosteric site for selective inhibition of the oncogenic protein tyrosine phosphatase Shp2" 54 : 497-504, 2015
• 25 Ahn JH, "Synthesis and biological evaluation of rhodanine derivatives as PRL-3 inhibitors" 16 : 2996-2999, 2006
• 26 Ren LG, "Substrate specificity of protein tyrosine phosphatases 1B, RPTP alpha, SHP-1, and SHP-2" 50 : 2339-2356, 2011
• 27 Feng Y, "Substrate specificity of human protein arginine methyltransferase 7(PRMT7) the importance of acidic residues in the double E loop" 289 : 32604-32616, 2014
• 28 Park H, "Structurebased virtual screening approach to identify novel classes of PTP1B inhibitors" 44 : 3280-3284, 2009
• 29 Guerreiro PS, "Structure-based virtual screening toward the discovery of novel inhibitors of the DNA repair activity of the human apurinic/apyrimidinic endonuclease 1" 88 : 915-925, 2016
• 30 Park H, "Structure-based virtual screening approach to the discovery of novel PTPMT1 phosphatase inhibitors" 22 : 1271-1275, 2012
• 31 Danishuddin M, "Structure-based screening of inhibitors against KPC-2: designing potential drug candidates against multidrug-resistant bacteria" 32 : 741-750, 2014
• 32 Black E, "Structure-based design of protein tyrosine phosphatase-1B inhibitors" 15 : 2503-2507, 2005
• 33 Kim KA, "Structure of human PRL-3, the phosphatase associated with cancer metastasis" 565 : 181-187, 2004
• 34 Saito H., "Structure and function of protein tyrosine phosphatases" 94 : 14-, 2004
• 35 Musharraf A, "Structural requirements of substrates for the PTP domain of Eya proteins" 12 : 174-174, 2006
• 36 Xiao JY, "Structural and functional analysis of PTPMT1, a phosphatase required for cardiolipin synthesis" 108 : 11860-11865, 2011
• 37 Andersen JN, "Structural and evolutionary relationships among protein tyrosine phosphatase domains" 21 : 7117-7136, 2001
• 38 Peti W, "Strategies to make protein serine/threonine (PP1, calcineurin) and tyrosine phosphatases (PTP1B) druggable: achieving specificity by targeting substrate and regulatory protein interaction sites" 23 : 2781-2785, 2015
• 39 Sheriff S, "Small molecule receptor protein tyrosine phosphatase gamma (RPTP gamma) ligands that inhibit phosphatase activity via perturbation of the tryptophan-proline-aspartate (WPD) loop" 54 : 6548-6562, 2011
• 40 Singh M, "Site-specific mutations localized in the D-E loop of the D1 protein of photosystem II affect phototolerance in Synechocystis sp. PCC 6803 containing psbAII gene" 40 : 108-113, 2003
• 41 Jung KJ, "Significance of protein tyrosine kinase/protein tyrosine phosphatase balance in the regulation of NF-kappa B signaling in the inflammatory process and aging" 47 : 983-991, 2009
• 42 Geetha N, "Signal integration and coincidence detection in the mitogen-activated protein kinase/extracellular signal-regulated kinase (ERK) cascade:concomitant activation of receptor tyrosine kinases and of LRP-1 leads to sustained ERK phosphorylation via downregulation of dual specificity phosphatases (DUSP1 and -6)" 286 : 25663-25674, 2011
• 43 Proschak E, "Shapelets: possibilities and limitations of shape-based virtual screening" 29 : 108-114, 2008
• 44 Chicco AJ, "Role of cardiolipin alterations in mitochondrial dysfunction and disease" 292 : C33-C44, 2007
• 45 Geng YX, "Research on ant colony algorithm optimization neural network weights blind equalization algorithm" 10 : 95-104, 2016
• 46 Morimura T, "Relative importance of the tyrosine phosphorylation sites of Disabled-1 to the transmission of Reelin signaling" 1304 : 26-37, 2009
• 47 Yang J, "Relation between the flexibility of the WPD loop and the activity of the catalytic domain of protein tyrosine phosphatase SHP-1" 84 : 47-55, 2002
• 48 Chagnon MJ, "Receptor tyrosine phosphatase sigma (RPTP sigma) regulates, p250GAP, a novel substrate that attenuates Rac signaling" 22 : 1626-1633, 2010
• 49 Horvat-Broecker A, "Receptor protein tyrosine phosphatases are expressed by cycling retinal progenitor cells and involved in neuronal development of mouse retina" 152 : 618-645, 2008
• 50 Gopalakrishnan K, "Ramachandran plot on the web (2.0)" 14 : 669-671, 2007
• 51 Laurie ATR, "Q-SiteFinder: an energybased method for the prediction of protein-ligand binding sites" 21 : 1908-1916, 2005
• 52 Bard-Chapeau EA, "Ptpn11/Sh p2 acts as a tumor suppressor in hepatocellular carcinogenesis" 19 : 629-639, 2011
• 53 Zhang ZY., "Protein-tyrosine phosphatases: biological function, structural characteristics, and mechanism of catalysis" 33 : 1-52, 1998
• 54 Lin JS, "Protein-tyrosine kinase and protein-serine/threonine kinase expression in human gastric cancer cell lines" 5 : 101-110, 1998
• 55 Cousin C, "Protein-serine/threonine/tyrosine kinases in bacterial signaling and regulation" 346 : 11-19, 2013
• 56 Zhang ZY, "Protein tyrosine phosphatases: structure and function, substrate specificity, and inhibitor development" 42 : 209-234, 2002
• 57 Alonso A, "Protein tyrosine phosphatases in the human genome" 117 : 699-711, 2004
• 58 Takahashi H, "Protein tyrosine phosphatases PTP delta, PTP sigma, and LAR: presynaptic hubs for synapse organization" 36 : 522-534, 2013
• 59 Tonks NK, "Protein tyrosine phosphatases - from housekeeping enzymes to master regulators of signal transduction" 280 : 346-378, 2013
• 60 Byrum CA, "Protein tyrosine and serine-threonine phosphatases in the sea urchin, Strongylocentrotus purpuratus: identification and potential functions" 300 : 194-218, 2006
• 61 Dudits D., "Protein phosphorylation as key control mechanism in plant cell division" 26 : 4-, 2004
• 62 Hou XB, "Protein flexibility in docking-based virtual screening: discovery of novel lymphoid-specific tyrosine phosphatase inhibitors using multiple crystal structures" 55 : 1973-1983, 2015
• 63 Cheney DL, "Protein ensemble-based lead docking: a comparison of FLO, GLIDE, GOLD and ICM in cross docking scenarios" 227 : U1029-, 2004
• 64 Bajusz D, "Property-based characterization of kinase-like ligand space for library design and virtual screening" 6 : 1898-1904, 2015
• 65 Demers JP, "Progress in correlation spectroscopy at ultra-fast magic-angle spinning:basic building blocks and complex experiments for the study of protein structure and dynamics" 40 : 101-113, 2011
• 66 Urbanek RA, "Potent reversible inhibitors of the protein tyrosine phosphatase CD45" 44 : 1777-1793, 2001
• 67 Takahashi H, "Postsynaptic TrkC and presynaptic PTP sigma function as a bidirectional excitatory synaptic organizing complex" 69 : 287-303, 2011
• 68 Doughty-Shenton D, "Pharmacological targeting of the mitochondrial phosphatase PTPMT1" 333 : 584-592, 2010
• 69 Cazzaniga G, "PTPN11 and RAS gene mutation pattern identifies an unique feature of upregulated RAS function in infant ALL" 104 : 996-, 2004
• 70 El-Kouhen K, "PTPMT1: connecting cardiolipin biosynthesis to mitochondrial function" 13 : 615-617, 2011
• 71 Nath AK, "PTPMT1 inhibition lowers glucose through succinate dehydrogenase phosphorylation" 10 : 694-701, 2015
• 72 Vercauteren M, "PTP1B: a new target for the treatment of the endothelial dysfunction in obesity and diabetes" 26 : S367-, 2008
• 73 Faux C, "PTP sigma binds and dephosphorylates neurotrophin receptors and can suppress NGF-dependent neurite outgrowth from sensory neurons" 1773 : 1689-1700, 2007
• 74 Innocenti F, "PRL-3, a phosphatase implied in cancer metastasis: structure and function" 13 : 127-, 2004
• 75 Al-Aidaroos AQO, "PRL-3 phosphatase and cancer metastasis" 111 : 1087-1098, 2010
• 76 Bardelli A, "PRL-3 expression in metastatic cancers" 9 : 5607-5615, 2003
• 77 de Beer TAP, "PDBsum additions" 42 : D292-D296, 2014
• 78 van Montfort RLM, "Oxidation state of the active-site cysteine in protein tyrosine phosphatase 1B" 423 : 773-777, 2003
• 79 Ostensen CG, "Overexpression of protein-tyrosine phosphatase PTP sigma is linked to impaired glucose-induced insulin secretion in hereditary diabetic Goto-Kakizaki rats" 291 : 945-950, 2002
• 80 Hashimoto Y, "Overexpression of Cdc25B, an androgen-receptor coactivator, in human prostate cancer" 169 : 84-85, 2003
• 81 Asthagiri D, "On the role of the conserved aspartate in the hydrolysis of the phosphocysteine intermediate of the low molecular weight tyrosine phosphatase" 126 : 12677-12684, 2004
• 82 Ding HY, "Norathyriol reverses obesity- and high-fat-dietinduced insulin resistance in mice through inhibition of PTP1B" 57 : 2145-2154, 2014
• 83 Oishi K, "Noonan syndrome-causative gain-of-function mutations in PTPN11 result in wing abnormalities and embryonic lethality in Drosophila" 55 : 270a-, 2004
• 84 Stockman BJ., "NMR spectroscopy as a tool for structure-based drug design" 33 : 109-151, 1998
• 85 Wei RR, "Mutational changes of conserved residues in the Q-loop region of transcription factor Rhogreatly reduce secondary site RNA-binding" 314 : 1007-1015, 2001
• 86 Lang BT, "Modulation of the proteoglycan receptor PTP sigma promotes recovery after spinal cord injury" 518 : 404-408, 2015
• 87 Balajee R, "Mining the information for structure based drug designing by relational database management notion" 6 : 1047-1054, 2009
• 88 Lee H, "Mining the function of protein tyrosine phosphatases in health and disease" 37 : 66-72, 2015
• 89 Huang BD, "MetaPocket: a meta approach to improve protein ligand binding site prediction" 13 : 325-330, 2009
• 90 Yin S, "MedusaScore: an accurate force field-based scoring function for virtual drug screening" 48 : 1656-1662, 2008
• 91 Ain QU, "Machine-learning scoring functions to improve structurebased binding affinity prediction and virtual screening" 5 : 405-424, 2015
• 92 Ashtawy HM, "Machine-learning scoring functions for identifying native poses of ligands docked to known and novel proteins" 16 (16): S3-, 2015
• 93 Astuti P, "MAPK pathway activation delays G(2)/M progression by destabilizing Cdc25B" 284 : 33781-33788, 2009
• 94 Yuan YX, "LigBuilder 2: a practical de novo drug design approach" 51 : 1083-1091, 2011
• 95 Davezac N, "Involvment of CDC25 phosphatases in growth control" 48 : 182-189, 2000
• 96 Nguyen PH, "Insulin-mimetic selaginellins from Selaginella tamariscina with protein tyrosine phosphatase 1B (PTP1B) inhibitory activity" 78 : 34-42, 2015
• 97 Derrien A, "Importance of tyrosine phosphorylation of RGS16 in the inhibition of G-proteincoupled MAP kinase stimulation" 105 : S172-S173, 2000
• 98 Macho AP, "Importance of tyrosine phosphorylation in receptor kinase complexes" 20 : 269-272, 2015
• 99 DeGnore JP, "Identification of the oxidation states of the active site cysteine in a recombinant protein tyrosine phosphatase by electrospray mass spectrometry using on-line desalting" 12 : 1457-1462, 1998
• 100 Zhang W, "Identification of the binding site of an allosteric ligand using STD-NMR, docking, and CORCEMAST calculations" 8 : 1629-1633, 2013
• 101 Martin KR, "Identification of small molecule inhibitors of PTPs through an integrative virtual and biochemical approach" 7 : e50217-, 2012
• 102 Zhang YM, "Identification of covalent binding sites targeting cysteines based on computational approaches" 13 : 3106-3118, 2016
• 103 Amor VM, "Identification of DUSP1/MKP1 mediated pathways in lung cancer progression" 6 : 69-70, 2008
• 104 Sotriffer C, "Identification and mapping of small-molecule binding sites in proteins: computational tools for structure-based drug design" 57 : 243-251, 2002
• 105 Li GB, "ID-Score:a new empirical scoring function based on a comprehensive set of descriptors related to protein-ligand interactions" 53 : 592-600, 2013
• 106 Zhang XC, "Gab2 phosphorylation by RSK inhibits Shp2 recruitment and cell motility" 33 : 1657-1670, 2013
• 107 Tonks NK., "From structure to function of protein tyrosine phosphatases" 358 : R377-, 1998
• 108 Li LW, "Form, function, and regulation of protein tyrosine phosphatases and their involvement in human diseases" 12 : 75-84, 2000
• 109 Korb O, "Empirical scoring functions for advanced protein-ligand docking with plants" 49 : 84-96, 2009
• 110 Wang Z, "Elevated PRL-3 expression was more frequently detected in the large primary gastric cancer and exhibits a poor prognostic impact on the patients" 135 : 1041-1046, 2009
• 111 Gruninger RJ, "Effect of ionic strength and oxidation on the P-loop conformation of the protein tyrosine phosphatase-like phytase, PhyAsr" 275 : 3783-3792, 2008
• 112 Ozkaral B, "Dynamic analysis of phosphatase 1B WPD loop" 98 : 440a-, 2010
• 113 Musumeci L, "Dual-specificity phosphatase 3deficiency or inhibition limits platelet activation and arterial thrombosis" 131 : 656-668, 2015
• 114 Bulavin DV, "Dual phosphorylation controls Cdc25 phosphatases and mitoticentry" 5 : 545-551, 2003
• 115 Kruger DM, "DrugScore(PPI) knowledge-based potentials used as scoring and objective function in protein-protein docking" 9 : e89466-, 2014
• 116 Wishart DS, "DrugBank: a comprehensive resource for in silico drug discovery and exploration" 34 : D668-D672, 2006
• 117 Niemi NM, "Downregulation of the mitochondrial phosphatase PTPMT1is sufficient to promote cancer cell death" 8 : e53803-, 2013
• 118 Yangmee Kim, "Docking Study of Biflavonoids, Allosteric Inhibitors of Protein Tyrosine Phosphatase 1B" 대한화학회 29 (29): 1479-1484, 2008
• 119 Sarvagalla S, "Disruption of protein-protein interactions: hot spot detection, structure-based virtual screening and in vitro testing for the anti-cancer drug target survivin" 6 : 31947-31959, 2016
• 120 Gui Q, "Disruption of Shp2 tyrosine phosphatase promotes Hes1/Stat3 complex in intestinal epithelia, contributing to enhanced self-renewal capacity and impaired differentiation in the crypt niche" 27 : S1159-, 2013
• 121 Park H, "Discovery of potent inhibitors of receptor protein tyrosine phosphatase sigma through the structure-based virtual screening" 22 : 6333-6337, 2012
• 122 Chen LW, "Discovery of a novel Shp2 protein tyrosine phosphatase inhibitor" 70 : 562-570, 2006
• 123 Lazo JS, "Discovery and biological evaluation of a new family of potent inhibitors of the dual specificity protein phosphatase Cdc25" 44 : 4042-4049, 2001
• 124 Lazo JS, "Discovery and biological evaluation of a new family of potent inhibitors of the dual specificity protein phosphatase Cdc25" 44 : 4042-4049, 2001
• 125 Kontaridis, "Deletion of Ptpn11 (Shp2) in cardiomyocytes causes dilated cardiomyopathy via effects on the extracellular signal-regulated kinase/mitogen-activated protein kinase and RhoA signaling pathways" 117 : 1423-1435, 2008
• 126 Moncho-Amor V, "DUSP1/MKP1 promotes angiogenesis, invasion and metastasis in non-small-cell lung cancer" 30 : 668-678, 2011
• 127 Khor GH, "DNA methylation profiling revealed promoter hypermethylation-induced silencing of p16, DDAH2and DUSP1 in primary oral squamous cell carcinoma" 10 : 1727-1739, 2013
• 128 Chen YY, "Cysteine S-nitrosylation protects proteintyrosine phosphatase 1B against oxidation-induced permanent inactivation" 283 : 35265-35272, 2008
• 129 Wang W, "Crystal structure of human protein tyrosine phosphatase SHP-1 in the open conformation" 112 : 2062-2071, 2011
• 130 Vincent I, "Constitutive Cdc25B tyrosine phosphatase activity in adult brain neurons with M phase-type alterations in Alzheimer’s disease" 105 : 639-650, 2001
• 131 Ten Eyck LF, "Conserved spatial patterns across the protein kinase family" 1784 : 238-243, 2008
• 132 Kesharwani RK, "Computationbased virtual screening for designing novel antimalarial drugs by targeting falcipain-III: a structure-based drug designing approach" 50 : 93-102, 2013
• 133 Hsieh JH, "Cheminformatics meets molecular mechanics: a combined application of knowledge-based pose scoring and physical force field-based hit scoring functions improves the accuracy of virtual screening" 52 : 16-28, 2010
• 134 Monteiro-Cardoso VF, "Cardiolipin profile changes are associated to the early synaptic mitochondrial dysfunction in Alzheimer’s disease" 43 : 1375-1392, 2015
• 135 Cortesio CL, "Calpain 2 and PTP1B function in a novel pathway with Src to regulate invadopodia dynamics and breast cancer cell invasion" 180 : 957-971, 2008
• 136 Draetta G, "CDC25 phosphatases and checkpoint controls" 38 : S116-, 2002
• 137 Dundas J, "CASTp: computed atlas of surface topography of proteins with structural and topographical mapping of functionally annotated residues" 34 : W116-W118, 2006
• 138 Zhu J, "Building and refining protein models within cryo-electron microscopy density maps based on homology modeling and multiscale structure refinement" 397 : 835-851, 2010
• 139 Seco J, "Binding site detection and druggability index from first principles" 52 : 2363-2371, 2009
• 140 Seo JH, "Automatic protein structure prediction system enabling rapid and accurate model building for enzyme screening" 45 : 218-225, 2009
• 141 Osterberg F, "Automated docking to multiple target structures:Incorporation of protein mobility and structural water heterogeneity in AutoDock" 46 : 34-40, 2002
• 142 Lim-Wilby M, "Automated de novo design with LUDI, minimizer, QSAR, and scoring functions: development and validation of autoLUDI" 228 : U509-, 2004
• 143 Zinker B, "Anti-diabetic effects of protein tyrosine phosphatase 1B (PTP1B) antisense treatment in a rodent model of diabetes: potential therapeutic benefit" 50 : A332-, 2001
• 144 Perron MD, "Allosteric noncompetitive small molecule selective inhibitors of CD45 tyrosine phosphatase suppress T-cell receptor signals and inflammation in vivo" 85 : 553-563, 2014
• 145 Hansen SK, "Allosteric inhibition of PTP1B activity by selective modification of a non-active site cysteine residue" 44 : 7704-7712, 2005
• 146 Tsai CJ, "Ahierarchial, building-block-based computational scheme for protein structure prediction" 45 : 513-523, 2001
• 147 Leung KT, "Activation of the JNK pathway promotes phosphorylation and degradation of Bim(EL) - a novel mechanism of chemoresistance in T-cell acute lymphoblastic leukemia" 29 : 544-551, 2008
• 148 Bentires-Alj M, "Activating mutations of the Noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia" 64 : 8816-8820, 2004
• 149 Lizunov AY, "Accounting for intraligand interactions in flexible ligand docking with a PMF-based scoring function" 55 : 2121-2137, 2015
• 150 Rettenmaier TJ, "A small-molecule mimic of a peptide docking motif inhibits the protein kinase PDK1" 111 : 18590-18595, 2014
• 151 Congreve M, "A rule of three for fragment-based lead discovery?" 8 : 876-877, 2003
• 152 Sharma B, "A positively charged side chain at position 154 on the beta 8-alpha E loop of HIV-1 RT is required for stable ternary complex formation" 31 : 5167-5174, 2003
• 153 Tailor P, "A novel isoform of the low molecular weight phosphotyrosine phosphatase, LMPTP-C, arising from alternative mRNA splicing" 262 : 277-282, 1999
• 154 Barradas D, "A comprehensive analysis of scoring functions for protein-protein docking" 24 : 250-251, 2015
• 155 Tonks NK, "A brake becomes an accelerator: PTP1B - a new therapeutic target for breast cancer" 11 : 214-216, 2007
• 156 Ul-Haq Z, "3D structure prediction of human beta 1-adrenergic receptor via threading-based homology modeling for implications in structure-based drug designing" 10 : e0122223-, 2015